Granza Bio

Granza Bio is a biotechnology company developing programmable therapeutics for the immune system, based on the discovery of "attack particles" — autonomous killing entities released by cytotoxic immune cells that carry effector proteins such as granzymes and perforins. The discovery originated in the laboratory of co-founder Prof. Michael Dustin, Professor of Molecular Immunology at the University of Oxford and director of research at the Kennedy Institute of Rheumatology. The company positions attack particles as combining the potency of cellular therapies with the off-the-shelf handling of antibody-based drugs, and describes an approach of re-arming exhausted immune cells with newly programmed ammunition.

A central element of the company's work is a delivery platform: a library of engineered precision "shells" designed to encapsulate and direct therapeutic cargo to specific tissues. The platform is described as addressing three problems — carrying varied cargo types (RNAs, proteins, attack particles), reaching a range of tissue sites, and avoiding immunological activation triggered by the delivery vehicle itself — and more broadly the challenges of tropism, immunogenicity and stability. A third-party directory profile adds that the vehicles are designed from non-immunogenic proteins equipped with a targeting receptor and are claimed to offer higher stability than conventional lipid nanoparticles.

In its Y Combinator launch materials, the company reported cancer-killing efficacy for attack particles in brain, ovarian, lung and skin cancer contexts, engineering to spare healthy cells, capability to cross the blood-brain barrier, and suitability for a platform approach spanning cancers, autoimmune diseases and infections. These claims are company-stated and are not accompanied in the available sources by clinical data.

Founding story

The company was founded in 2024 by researchers from the University of Oxford: Dr. Ashwin Nandakumar (CEO), who holds a DPhil in Oncology from Oxford, worked as a Cancer Research UK post-doctoral researcher at Oxford and the Institute of Cancer Research in London, and has set up oncology clinical trials; Dr. Ashwin Jainarayanan (CSO), a Clarendon Scholar with a DPhil in Interdisciplinary Bioscience and research experience on immune-cell-derived attack particles; and Prof. Michael Dustin, whose Oxford lab discovered attack particles. The founders state that after identifying the therapeutic potential of attack particles they found they lacked an effective system for packaging and delivering them to specific tissues, which led to the development of the engineered delivery shell platform.

Business model

Sources describe a therapeutics/platform biotechnology model: developing a proprietary delivery shell platform plus a lead candidate based on attack particles. The company invites partnership and licensing inquiries, indicating openness to partnered or licensed use of the delivery platform alongside internal drug development. No pricing, revenue or commercial terms are disclosed in the sources.

Not disclosed in the available sources; the company is at a pre-clinical/discovery stage with venture funding and solicits partnership and licensing enquiries.

Traction

Traction reported in the sources is financial and organisational rather than clinical: an oversubscribed $7.14M seed round closed in July 2024 led by Felicis and Refactor with Y Combinator and numerous angels; participation in the YC Winter 2024 batch; and a team size of eight. One directory lists cumulative funding of $7.5M across two rounds. No clinical trials, revenue or partnership agreements are documented.

Latest developments

The most recent documented development in the sources is the July 2024 announcement of the $7.14M seed financing to advance delivery of cancer treatments and genetic medicines, alongside the company's Y Combinator Winter 2024 listing, which continued to show the company as active with eight employees.